Harrow (HROW) Expected to Post Earnings on Monday

Harrow (NASDAQ:HROW) is expected to issue its Q3 2026 results after the market closes on Monday, November 9th. Analysts expect the company to post earnings of $0.17 per share and revenue of $98.47 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 10, 2026 at 8:00 AM ET.

Harrow (NASDAQ:HROW) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.28). The firm had revenue of $70.66 million for the quarter, compared to analyst estimates of $70.35 million. Harrow had a negative return on equity of 38.00% and a negative net margin of 13.51%.

Harrow Stock Performance

NASDAQ HROW opened at $28.04 on Monday. The stock has a fifty day simple moving average of $32.86 and a 200-day simple moving average of $38.42. Harrow has a twelve month low of $26.96 and a twelve month high of $54.85. The company has a current ratio of 2.24, a quick ratio of 2.08 and a debt-to-equity ratio of 19.70. The stock has a market cap of $1.05 billion, a PE ratio of -28.04 and a beta of 0.18.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on HROW shares. Zacks Research raised Harrow from a “strong sell” rating to a “hold” rating in a research report on Wednesday, September 9th. BTIG Research reaffirmed a “buy” rating and set a $63.00 price target on shares of Harrow in a report on Wednesday, October 7th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Harrow in a report on Friday, October 16th. Leerink Partners initiated coverage on Harrow in a research note on Wednesday, September 9th. They issued an “outperform” rating and a $45.00 target price on the stock. Finally, Wall Street Zen raised shares of Harrow from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Seven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Harrow currently has a consensus rating of “Moderate Buy” and an average price target of $66.17.

Insider Activity

In related news, insider Amir Shojaei sold 11,250 shares of Harrow stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $40.00, for a total value of $450,000.00. Following the sale, the insider directly owned 11,250 shares in the company, valued at $450,000. This trade represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 12.80% of the company’s stock.

About Harrow

Harrow, Inc is an ophthalmic pharmaceutical company focused on developing, acquiring, and commercializing prescription therapies for eye care. The company’s portfolio addresses conditions and procedures involving the ocular surface, anterior segment, and retina, with products intended for use by ophthalmologists and other eye-care professionals.

Harrow’s commercial products include VEVYE, a cyclosporine ophthalmic solution for the treatment of dry eye disease, and IHEEZO, a chloroprocaine hydrochloride ophthalmic gel used for ocular surface anesthesia during ophthalmic procedures.